Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

Thangirala Sudha, Dhruba J. Bharali, Murat Yalcin, Noureldien H E Darwish, Melis Debreli Coskun, Kelly A. Keating, Hung Yun Lin, Paul J. Davis, Shaker A. Mousa

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.

Original languageEnglish
Pages (from-to)195-205
Number of pages11
JournalNanomedicine
Volume12
Issue number3
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Heterografts
tumor
Nanoparticles
Cisplatin
Tumors
drug
cancer
Acids
acid
Bearings (structural)
Neoplasms
Endothelial cells
Cells
Urinary Bladder Neoplasms
Pharmaceutical Preparations
efficiency
tetraiodothyroacetic acid
nanoparticle
Nude Mice
Integrins

Keywords

  • cisplatin
  • integrin
  • nanotetrac
  • NDAT
  • tetraiodothyroacetic acid
  • urinary bladder carcinoma

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Bioengineering
  • Biomedical Engineering
  • Development
  • Materials Science(all)

Cite this

Sudha, T., Bharali, D. J., Yalcin, M., Darwish, N. H. E., Coskun, M. D., Keating, K. A., ... Mousa, S. A. (2017). Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac. Nanomedicine, 12(3), 195-205. https://doi.org/10.2217/nnm-2016-0315

Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac. / Sudha, Thangirala; Bharali, Dhruba J.; Yalcin, Murat; Darwish, Noureldien H E; Coskun, Melis Debreli; Keating, Kelly A.; Lin, Hung Yun; Davis, Paul J.; Mousa, Shaker A.

In: Nanomedicine, Vol. 12, No. 3, 01.02.2017, p. 195-205.

Research output: Contribution to journalArticle

Sudha, T, Bharali, DJ, Yalcin, M, Darwish, NHE, Coskun, MD, Keating, KA, Lin, HY, Davis, PJ & Mousa, SA 2017, 'Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac', Nanomedicine, vol. 12, no. 3, pp. 195-205. https://doi.org/10.2217/nnm-2016-0315
Sudha T, Bharali DJ, Yalcin M, Darwish NHE, Coskun MD, Keating KA et al. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac. Nanomedicine. 2017 Feb 1;12(3):195-205. https://doi.org/10.2217/nnm-2016-0315
Sudha, Thangirala ; Bharali, Dhruba J. ; Yalcin, Murat ; Darwish, Noureldien H E ; Coskun, Melis Debreli ; Keating, Kelly A. ; Lin, Hung Yun ; Davis, Paul J. ; Mousa, Shaker A. / Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac. In: Nanomedicine. 2017 ; Vol. 12, No. 3. pp. 195-205.
@article{2d53cb84812b482c8390a282250d7068,
title = "Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac",
abstract = "Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.",
keywords = "cisplatin, integrin, nanotetrac, NDAT, tetraiodothyroacetic acid, urinary bladder carcinoma",
author = "Thangirala Sudha and Bharali, {Dhruba J.} and Murat Yalcin and Darwish, {Noureldien H E} and Coskun, {Melis Debreli} and Keating, {Kelly A.} and Lin, {Hung Yun} and Davis, {Paul J.} and Mousa, {Shaker A.}",
year = "2017",
month = "2",
day = "1",
doi = "10.2217/nnm-2016-0315",
language = "English",
volume = "12",
pages = "195--205",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

AU - Sudha, Thangirala

AU - Bharali, Dhruba J.

AU - Yalcin, Murat

AU - Darwish, Noureldien H E

AU - Coskun, Melis Debreli

AU - Keating, Kelly A.

AU - Lin, Hung Yun

AU - Davis, Paul J.

AU - Mousa, Shaker A.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.

AB - Aim: Nano-diamino-tetrac (NDAT) targets a receptor on integrin αvβ3; αvβ3 is generously expressed by cancer cells and dividing endothelial cells and to a small extent by nonmalignant cells. The tetrac (tetraiodothyroacetic acid) of NDAT is covalently bound to a poly(lactic-co-glycolic acid) nanoparticle that encapsulates anticancer drugs. We report NDAT delivery efficiency of cisplatin to agent-susceptible urinary bladder cancer xenografts. Materials & methods: Cisplatin-loaded NDAT (NDAT-cisplatin) was administered to xenograft-bearing nude mice. Tumor size response and drug content were measured. Results: Intratumoral drug concentration was up to fivefold higher (p < 0.001) in NDAT-cisplatin-exposed lesions than with conventional systemic administration. Tumor volume reduction achieved was NDAT-cisplatin > NDAT without cisplatin > cisplatin alone. Conclusion: NDAT markedly enhances cisplatin delivery to urinary bladder cancer xenografts and increases drug efficacy.

KW - cisplatin

KW - integrin

KW - nanotetrac

KW - NDAT

KW - tetraiodothyroacetic acid

KW - urinary bladder carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85010383217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010383217&partnerID=8YFLogxK

U2 - 10.2217/nnm-2016-0315

DO - 10.2217/nnm-2016-0315

M3 - Article

VL - 12

SP - 195

EP - 205

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 3

ER -